Summary: In a phase 1, randomised, double-blind, placebo-controlled study of 50 obese Chinese adults without diabetes (BMI greater than or equal to 28 kg/m squared), titrated once-daily noiiglutide (SHR20004) was well tolerated and produced dose-related mean weight loss of up to -7.46 kg versus -1.89 kg with placebo. As an early-phase safety and dose-finding study, no formal significance testing was reported.
PICO Summary
| Element | Detail |
|---|---|
| Population | 50 obese adults without diabetes mellitus (BMI greater than or equal to 28 kg/m squared); phase 1 randomised, double-blind, placebo-controlled study; China. |
| Intervention | Noiiglutide (SHR20004), a novel GLP-1 receptor agonist, given as a once-daily injection using a titration method over 3 to 6 weeks to a final dose of 0.18, 0.24, 0.30 or 0.36 mg/day; 8 participants per dose group received active drug (32 active in total). |
| Comparison | Placebo; 2 participants per dose group (10 placebo recipients pooled across the four dose groups). |
| Outcome | Mean weight change from baseline: placebo -1.89 kg; active groups -3.26, -5.45, -4.35 and -7.46 kg, with reductions tending to increase with longer administration. Pharmacokinetics: steady state reached after 4 days of daily dosing with no significant accumulation; mean elimination half-life 9.90 to 11.8 h at steady state. Safety: most treatment-emergent adverse events were mild to moderate, with no serious adverse events and no withdrawals. No p-values, confidence intervals, ARR or NNT were reported (early-phase study, small per-group n). |
Expert Commentary
This is an early-phase, dose-finding study whose purpose is to establish safety, tolerability and pharmacokinetics rather than to prove efficacy. On that brief it reads positively: titrated noiiglutide was well tolerated, the adverse-event profile was dominated by the expected mild-to-moderate gastrointestinal effects, no serious events or withdrawals were recorded, and predictable pharmacokinetics with steady state by day 4 and a half-life near 10 to 12 hours support once-daily dosing. The weight changes are encouraging and appear dose-related, reaching -7.46 kg at the top dose against -1.89 kg with placebo. The central limitation is that this is a small phase 1 study, with roughly eight actively treated participants per dose group and no significance testing, so the weight figures are descriptive signals, not demonstrated efficacy, and the irregular ordering across doses should temper any dose-response claim. The study was sponsored and co-authored by the manufacturer, which warrants the usual caution despite the double-blind design. Can I use this with my patients? Not yet; noiiglutide is investigational and these data cannot guide treatment decisions outside a trial. The verdict is a clean safety and pharmacokinetic signal that justifies adequately powered phase 2 and 3 trials with active comparators, longer follow-up and prespecified statistical endpoints before any role in obesity management can be judged.
References
Zou Y, Jiang F, Sun C, Zhao C, Qian H, Jia J, et al. Safety, pharmacokinetics and pharmacodynamics of multiple-dose noiiglutide (SHR20004), a novel GLP-1 receptor agonist, in Chinese obese subjects without diabetes mellitus. Diabetes Obes Metab. 2025;27(2):816-824. doi:10.1111/dom.16080